Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.
Ontology highlight
ABSTRACT: Background: Obesity has been associated with worse outcomes in patients with clinically localized urothelial cancer. However, this impact has not been evaluated in metastatic disease. Objective: To assess the impact of obesity on outcomes of patients with metastatic urothelial cancer. Methods: Data from 537 patients were aggregated from eight phase II and phase III clinical trials investigating first-line cisplatin-based combination therapy in metastatic urothelial cancer. Chemotherapy regimen, adverse events, treatment response, and survival outcomes were compared across body mass index (BMI) and body surface area (BSA) categories. Results: BMI was classified according to WHO criteria (<18.5 underweight, 18.5-24.99 normal weight, 25-29.99 overweight, >30 obese)
SUBMITTER: Leiter A
PROVIDER: S-EPMC4969712 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA